Orlistat Administration and Usage

Dosage and Administration

• The American Gastroenterological Association recommends taking orlistat during or within 1 hour after meals containing fat, with a prescription strength of 120 mg capsules taken three times daily, and a maximum daily dose not exceeding 3 capsules daily 1
• Patients should take a daily multivitamin containing fat-soluble vitamins (A, D, E, K) at bedtime or at least 2 hours apart from orlistat to prevent vitamin deficiencies, as recommended by the American Gastroenterological Association 1, 2
• A reduced-calorie, low-fat diet (≤30% of calories from fat) should be used in conjunction with orlistat, as suggested by the American Gastroenterological Association 1, 2

Treatment Considerations

• Orlistat is indicated for weight loss in adults aged 18 years and older with a BMI ≥30 kg/m² (obese) or BMI ≥28 kg/m² (overweight) with weight-related comorbidities, as suggested by the American Gastroenterological Association 2
• The American Gastroenterological Association suggests against routine use of orlistat due to modest weight loss benefits (2.81 kg more than placebo) and significant gastrointestinal side effects (occurring in 70-80% of users), but patients who place high value on potential small weight loss and low value on GI adverse effects may reasonably choose treatment with orlistat 1, 2, 3
• Common side effects include oily spotting/stool, fecal urgency, flatulence with discharge, fecal incontinence, and increased defecation, which are directly related to its mechanism of blocking fat absorption 4, 3
• Approximately 4% of patients discontinue orlistat due to gastrointestinal complaints, compared to 1% with placebo 3
• Orlistat can significantly affect absorption of lipophilic medications when taken simultaneously, including cyclosporine, and medications that may interact with orlistat should be taken at least 2 hours before or after orlistat 3, 2
• Regular assessment of gastrointestinal symptoms, periodic liver function monitoring, and evaluation of fat-soluble vitamin levels if treatment extends beyond short-term use are recommended, and the FDA has added a label warning about potential serious liver injury with orlistat use 3, 1
• Contraindications for orlistat use include pregnancy, breastfeeding, chronic malabsorption syndrome, cholestasis, patients with cholelithiasis (gallstones), or with concurrent use of cyclosporine, warfarin, or antiepileptic drugs 5, 4
• Most weight loss occurs in the first 6 months of treatment, and if 5% weight loss is not achieved after 12 weeks, consideration should be given to discontinuing orlistat 1